

RESEARCH ARTICLE


# Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies



Abdullah O. Khan<sup>1,2</sup>, Antonio Rodriguez-Romera<sup>2</sup>, Jasmeet S. Reyat<sup>1</sup>, Aude-Anais Olijnik<sup>2</sup>, Michela Colombo<sup>2</sup>, Guanlin Wang<sup>2,3</sup>, Wei Xiong Wen<sup>2,3</sup>, Nikolaos Sousos<sup>2,4</sup>, Lauren C. Murphy<sup>2</sup>, Beata Grygielska<sup>1</sup>, Gina Perrella<sup>1</sup>, Christopher B. Mahony<sup>5</sup>, Rebecca E. Ling<sup>6</sup>, Natalina E. Elliott<sup>6</sup>, Christina Simoglou Karali<sup>2</sup>, Andrew P. Stone<sup>7</sup>, Samuel Kemble<sup>5</sup>, Emily A. Cutler<sup>8</sup>, Adele K. Fielding<sup>8</sup>, Adam P. Croft<sup>5</sup>, David Bassett<sup>9</sup>, Gowthaman Poologasundarampillai<sup>10</sup>, Anindita Roy<sup>6</sup>, Sarah Gooding<sup>2,4</sup>, Julie Rayes<sup>1</sup>, Kellie R. Machlus<sup>7</sup>, and Bethan Psaila<sup>2,4</sup>

Downloaded from <http://aacnjournals.org/cancerdiscovery/article-pdf/13/2/364/3268892/364.pdf> by guest on 30 October 2023

Illustration by Anna Dunn



## ABSTRACT

A lack of models that recapitulate the complexity of human bone marrow has hampered mechanistic studies of normal and malignant hematopoiesis and the validation of novel therapies. Here, we describe a step-wise, directed-differentiation protocol in which organoids are generated from induced pluripotent stem cells committed to mesenchymal, endothelial, and hematopoietic lineages. These 3D structures capture key features of human bone marrow—stroma, lumen-forming sinusoids, and myeloid cells including proplatelet-forming megakaryocytes. The organoids supported the engraftment and survival of cells from patients with blood malignancies, including cancer types notoriously difficult to maintain *ex vivo*. Fibrosis of the organoid occurred following TGF $\beta$  stimulation and engraftment with myelofibrosis but not healthy donor-derived cells, validating this platform as a powerful tool for studies of malignant cells and their interactions within a human bone marrow-like milieu. This enabling technology is likely to accelerate the discovery and prioritization of novel targets for bone marrow disorders and blood cancers.

**SIGNIFICANCE:** We present a human bone marrow organoid that supports the growth of primary cells from patients with myeloid and lymphoid blood cancers. This model allows for mechanistic studies of blood cancers in the context of their microenvironment and provides a much-needed *ex vivo* tool for the prioritization of new therapeutics.

See related commentary by Derecka and Crispino, p. 263.

## INTRODUCTION

The specialized bone marrow microenvironment maintains and regulates hematopoiesis, enabling an adequate supply of blood cells to meet changing physiologic requirements throughout life. Perturbations in the bone marrow hematopoietic niche contribute to the initiation and propagation of hematologic malignancies. In addition, the stromal remodeling that occurs as a consequence of blood cancers contributes to bone marrow failure (1–4). Modeling bone marrow dysfunction is challenging, particularly in the context of human diseases. *In vitro* studies are often limited to 2D systems and simple cocultures, in which the relevant cell types are absent, and many human diseases are inadequately reproduced by mouse models. Patient-derived xenografts have been used to model disease and validate targets *in vivo*, but some malignancies and hematologic cell subtypes do not engraft well, even when humanized murine models are used (5–11).

Advances have been made in modeling certain marrow components on “biochips” (12–16), but the lack of specialized stroma, vascularization, and active blood cell generation remains a limitation with these methods. Coculture with bone marrow mesenchymal stromal cells (MSC) can support hematopoietic cell growth, either in 2D or in 3D with the addition of extracellular matrix support (17–19). Although beneficial, these approaches are limited in terms of the elements of the bone marrow that are incorporated, as well as their scalability and reproducibility due to the limited availability and interdonor variability of primary bone marrow MSCs. Improved *in vitro* systems are therefore required to enable more detailed mechanistic studies of human hematopoiesis, and to allow for the functional interrogation of the pathways and cross-talk that drive bone marrow malignancies.

The development and application of organoids—self-organizing, 3D, living multilineage structures—have the potential to facilitate translational research by enabling

<sup>1</sup>Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Birmingham, United Kingdom.

<sup>2</sup>MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine and National Institute of Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.

<sup>3</sup>Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

<sup>4</sup>Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

<sup>5</sup>Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

<sup>6</sup>MRC Weatherall Institute of Molecular Medicine, Department of Paediatrics and National Institute of Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.

<sup>7</sup>Vascular Biology Program, Boston Children’s Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts.

<sup>8</sup>University College London Cancer Institute, London, United Kingdom.

<sup>9</sup>Healthcare Technologies Institute, School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom.

<sup>10</sup>School of Dentistry, Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.

<sup>11</sup>Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

**Corresponding Authors:** Bethan Psaila, Department of Haematology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. Phone: 44(0)1865 222340; E-mail: Bethan.psaila@ndcls.ox.ac.uk; Abdullah O. Khan, Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. Phone: 44 (0)7852 311295; E-mail: a.khan.4@bham.ac.uk; and Kellie R. Machlus, Vascular Biology Program, Boston Children’s Hospital, Department of Surgery, Harvard Medical School, Boston, MA. Phone: 609-217-6618; E-mail: Kellie.Machlus@childrens.harvard.edu

*Cancer Discov* 2023;13:364–85

**doi:** 10.1158/2159-8290.CD-22-0199

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

©2022 The Authors; Published by the American Association for Cancer Research

genetic screens and pharmacologic modulation of disease pathobiology (20). Our goal was to generate a vascularized human bone marrow–like organoid that contains key hematopoietic niche elements and supports active endogenous hematopoiesis, as well as the growth and survival of hematopoietic cells from adult donors, including malignant cell types that are difficult to grow and study *ex vivo*. Such a system would offer a scalable and highly manipulable human model for mechanistic studies and drug development and, importantly, may reduce dependence on animal models.

To achieve this, we optimized a protocol in which human induced pluripotent stem cells (iPSC) generate mesenchymal elements, myeloid cells, and “sinusoidal-like” vasculature in a format that resembles the cellular, molecular, and spatial architecture of myelopoietic bone marrow. We confirmed the homology of these organoids to human bone marrow using multimodal imaging approaches and single-cell RNA sequencing (scRNA-seq). Crucially, in addition to modeling physiologic hematopoietic cell–niche interactions, we showed that the organoids supported the engraftment and survival of healthy and malignant hematopoietic cells from human donors, and enabled the screening of inhibitors of bone marrow fibrosis, a complication that occurs in patients with certain blood cancers and is associated with poor prognosis.

This platform addresses a long-standing need for 3D human bone marrow models for translational research in which both niche and hematopoietic components are species and cell context specific and creates a dynamic platform for high-throughput drug screening and studies aiming to understand disease pathways.

## RESULTS

### Mixed-Matrix Hydrogels Containing Matrigel and Type I and IV Collagens Are Optimal for the Production of Vascularized, Myelopoietic Organoids

To mimic the central bone marrow space (Fig. 1A), we devised a four-stage workflow to generate mesenchymal, vascular, and myelopoietic marrow components. Human iPSCs were allowed to form nonadherent mesodermal aggregates (phase I, days 0–3; Fig. 1B) before commitment to vascular and hematopoietic lineages (phase II, days 3–5; Fig. 1B). The resulting cell aggregates were then embedded in mixed collagen–Matrigel hydrogels to induce vascular sprouting (phase III, days 5–12; Fig. 1B). At day 12, sprouts were collected individually and cultured to form bone marrow organoids in 96-well ultralow attachment (ULA) plates (phase IV, day 12 onward; Fig. 1B).


Hydrogels comprising Matrigel plus type I collagen have previously been used to support the formation of iPSC-derived blood vessel organoids (21). However, type IV collagen is more permissive than type I collagen for myeloid and megakaryocyte maturation in standard 2D *in vitro* culture systems (22, 23). We therefore compared hydrogels containing type I and/or type IV collagen plus Matrigel for the generation of stromal, endothelial, and myeloid lineages. Distinct immunophenotypic hematopoietic stem

and progenitor cell (HSPC; CD34<sup>+</sup> Lin<sup>−</sup>), myelomonocytic (CD34<sup>−</sup> CD11b<sup>+</sup> Lin<sup>+</sup>), megakaryocyte (CD34<sup>−</sup> Lin<sup>−</sup> CD41<sup>+</sup> CD42b<sup>+</sup>), endothelial (CD31<sup>+</sup> CD144<sup>+</sup>), erythroid (CD34<sup>−</sup> Lin<sup>−</sup> CD71<sup>+</sup> CD235a<sup>+</sup>), and MSC (CD31<sup>−</sup> CD140b<sup>+</sup> VCAM1<sup>+</sup> LepR<sup>+</sup>) populations were detected when organoids were digested at day 18 of differentiation (Fig. 1C–E). Organoids developed in collagen type I–only hydrogels contained the highest fraction of HSPCs but a low proportion of myelomonocytic cells and megakaryocytes, and no MSCs, whereas collagen type IV and collagen type I + IV hydrogel–derived organoids yielded significantly larger myeloid and MSC populations, indicating that the addition of collagen IV created more favorable conditions for multilineage differentiation (Fig. 1D and E; Supplementary Fig. S1A).

The hematopoietic niche contains a dense network of sinusoidal vessels, and specialized sinusoidal endothelium regulates stem cell self-renewal and differentiation, progenitor maturation, and platelet generation (24, 25). To assess vascularization of the organoids, we measured the degree of endothelial sprouting. Vascular sprout radii were significantly smaller in collagen type IV–only hydrogels compared with collagen types I–only and I + IV (average radius of  $203.6 \pm 14.61 \mu\text{m}$  vs.  $345.9 \pm 32.11 \mu\text{m}$  vs.  $476.3 \pm 28.82 \mu\text{m}$ , respectively; Fig. 1F), and the density of CD34 and CD144 [Vascular Endothelial (VE)-Cadherin]–positive sprouts was significantly lower in collagen IV–only hydrogels (Fig. 1G). To assess the vascularization and cellular architecture of the whole organoid in 3D, organoids were mounted in agarose and cleared with Ethyl Cinnamate for confocal Z-stack imaging. This revealed an elaborate network of UAE1<sup>+</sup> CD144<sup>+</sup> vessels throughout the collagen I + IV–derived organoids (Fig. 1H–J). In addition to CD34<sup>+</sup> HSPCs (Fig. 1H), CD41<sup>+</sup> megakaryocytes (Fig. 1I) and CD71<sup>+</sup> erythroid cells (Fig. 1J) were distributed throughout the organoid volume and closely associated with the endothelium, as occurs in the native bone marrow.


### Addition of VEGFC Induces Specialization of Organoid Vasculature to a Bone Marrow Sinusoid-like Phenotype

Having determined that collagen I + IV Matrigel hydrogels enabled multilineage differentiation and the generation of a 3D vascular network, we sought to determine the optimal balance of endothelial growth factor support to generate organoid vasculature that resembles bone marrow sinusoids (24, 25). VEGFA is a key regulator of blood vessel formation in health and disease, acting via the VEGF receptors VEGFR1 and 2 (26). Bone marrow sinusoidal endothelial cells express VEGFR1 and 2 as well as VEGFR3 (27), and VEGFC—the main ligand for VEGFR3—was recently demonstrated to maintain the perivascular hematopoietic niche in murine bone marrow (28). We therefore tested the effect of adding VEGFC to the vascular sprouting phase (day 5; Fig. 2A). The addition of VEGFC significantly increased the expression of *FLT4* (encoding VEGFR3) in the organoids, as well as HSPC adhesion molecules (VCAM1 and ITGA4) and HSPC-supporting growth factors and chemotactic cytokines (CXCR4 and FGF4; Fig. 2B). Supplementation with VEGFC in addition to VEGFA also induced retention of CD34 expression on organoid vessels, similar to native adult bone marrow vessels, whereas organoids stimulated with VEGFA alone expressed



**Figure 1.** Mixed-matrix hydrogels containing Matrigel and type I and IV collagens are optimal for production of vascularized, myelopoietic organoids. **A**, (i) Central bone marrow is a complex tissue including MSC, endothelial, hematopoietic stem and progenitor cell (HSC/HSPCs), and myeloid and lymphoid subsets. (ii) Hematoxylin and eosin-stained section and (iii) model of human bone marrow highlighting the diverse hematopoietic and stromal cell types (created using Biorender.com). **B**, Differentiation workflow, in which iPSC aggregates undergo mesodermal induction (days 0–3) and commitment to hematopoietic and vascular lineages (days 3–5). Cell aggregates are then embedded in mixed-matrix hydrogels comprised of Matrigel and collagen I, collagen IV, or collagen I + IV mix at a 40:60 ratio to support vascular sprouting. Key media components are listed for each phase. (continued on next page)

Downloaded from <http://aacrjournals.org/cancerdiscovery/article-pdf/1/3/364/3296892/364.pdf> by guest on 30 October 2023




**Figure 1. (Continued)** Gating strategy (C) and quantification (D) of stromal and hematopoietic cell types in day 18 organoids supported by Matrigel + collagen type I-only, collagen IV-only, and collagen I + IV hydrogels. MK, megakaryocyte. E, Distribution of lineages as fractions of the whole organoid population. F, Radius of endothelial sprouts. (continued on following page)

CD34 during vessel sprouting (days 5–12; Fig. 1G) but lost CD34 expression by day 18 (Figs. 1H and 2C).

Organoid vessels formed clear lumens, containing extravasating hematopoietic cells (Fig. 2D and E), confirmed by multiplexed immunostaining to identify CD45<sup>+</sup> and CD71<sup>+</sup> hematopoietic cells within the lumen of UEA1<sup>+</sup> sinusoidal


vessels (Fig. 2F). A hallmark of the bone marrow perivascular niche *in vivo* is the close association of megakaryocytes with sinusoidal endothelium, where they extend long, beaded proplatelet extensions into the vessel lumen (Fig. 2G). These extensions subsequently generate platelet buds under shear forces (Fig. 2G; ref. 29). Cryosections of the bone marrow



**Figure 1. (Continued)** **G**, Sprouting day 12 organoids immunostained for nuclei (DAPI), CD34, and CD144 (VE-cadherin). **H–J**, Whole organoid Z-stack imaging acquired at day 18 showing CD34<sup>+</sup> HSPCs and UEA1<sup>+</sup> vessels that are negative for CD34 (**H**), CD41<sup>+</sup> megakaryocytes (**I**), and CD71<sup>+</sup> erythroid cells dispersed throughout the organoids and associating with CD144<sup>+</sup>/UEA1<sup>+</sup> vasculature (**J**). \*,  $P < 0.05$ ; \*\*,  $P < 0.001$  for one-way ANOVA with multiple comparisons [Fisher least significant difference (LSD)];  $n = 3$  for endothelial sprout radius measurements. Two-way ANOVA with multiple comparisons (Fisher LSD);  $n = 3$  (3 independent differentiations, 15 pooled organoids each) for flow cytometry analysis. Representative images are shown. See also Supplementary Fig. S1.

organoids stained for CD41<sup>+</sup> MKs, CD144<sup>+</sup> endothelium, and CD140b<sup>+</sup> MSCs/fibroblasts demonstrated classic proplatelet protrusions in association with the vessels (Fig. 2H and I), with remarkable similarity to previously published *in vivo* images of thrombopoiesis occurring in calvarial bone marrow (29). Volumetric imaging of whole-mount organoids demonstrated that these cells were organized in 3D in an

extensive endothelial network invested with perivascular CD140b<sup>+</sup> fibroblasts/MSCs. A higher number of megakaryocytes were observed in close proximity (5  $\mu$ m) to vessels in VEGFA + C-stimulated organoids than in VEGFA-only organoids (Supplementary Fig. S1B), consistent with the increased expression of chemotactic factors and adhesion proteins in VEGFA + C organoids (Fig. 2B). Together, these



data indicate that the addition of VEGFC improved vascularization of the organoids and hematopoietic support.

### scRNA-seq Confirmed that Hematopoietic and Stromal Cell Lineages within Organoids Have Transcriptional Homology to Human Hematopoietic Tissues

To compare the cell types and molecular profiles of the organoids to human hematopoietic tissues, scRNA-seq was performed on a total of 26,648 cells from 3 independent organoid differentiations using VEGFA-only and VEGFA + C protocols. After quality control (see Methods), 19,506 cells (10,205 from VEGFA only and 9,301 from VEGFA + C) were included in downstream analyses. Distinct populations of key hematopoietic and stromal cell subtypes were identified, including HSPC, erythroid, neutrophil, monocyte, megakaryocyte, eosinophil/basophil/mast (EBM), fibroblast, endothelial cell, and MSC (Fig. 3A; Supplementary Table S1), annotated using gene set enrichment analysis with a curated list of 64 published gene sets (Fig. 3B; Supplementary Table S2; refs. 30, 31), as well as the expression of canonical marker genes (Fig. 3C). Erythroid, megakaryocytic, monocytic/neutrophil, and EBM populations demonstrated expression of *GYPA* and *KLF1*, *PF4* and *PPBP*, *CD14* and *RUNX1*, and *TPS2* and *KIT*, respectively (Fig. 3C).

Within stromal cell subsets, expression of *COL3A1*, platelet-derived growth factors (*PDGFRA/B*), and the key HSPC niche factor *CXCL12* (SDF-1) was observed in fibroblasts and MSCs, with particularly high expression of *CXCL12* in the MSCs, suggesting a key role for MSCs in homing and maintenance of HSPCs to perivascular regions of the organoids (Fig. 3C; Supplementary Fig. S2A and S2B). High expression of *PECAM1*, *CDH5*, and *ENG* was detected in endothelial cells, confirming vascular specification (Fig. 3C; Supplementary Fig. S2A and S2B). The relative frequency of cell types in VEGFA-only organoids was broadly similar to that of VEGFA + C organoids, with a relative increase in abundance of endothelial and erythroid cells captured from organoids grown in the VEGFA + C condition (Supplementary Fig. S2C).

Trajectory analysis using a force-directed graph (FDG) showed that the organoids contained cells recapitulating the three main routes of hematopoietic myeloid differentiation (Fig. 3D; Supplementary Fig. S2D), similar to observations in human bone marrow (31). FDG analysis of the stromal cell populations showed independent routes of differentiation for endothelium and MSCs/fibroblasts as expected (Fig. 3E; Supplementary Fig. S2E).


To determine the transcriptional similarity of the bone marrow organoid to native human hematopoietic tissues, organoid scRNA-seq data were projected onto published single-cell datasets of cells isolated from adult human bone marrow (31, 32) and from fetal liver and fetal bone marrow (33) using the Symphony package (34). This revealed an extensive overlap of organoid-derived cells with HSPCs, myeloid subsets, fibroblasts/MSCs, and endothelial cell types, with the predicted cell types matching the cluster annotations (Fig. 3F; Supplementary Fig. S3A–S3C).


To explore the transcriptional similarity between the stromal support elements of the organoids with that of native human bone marrow in more detail, we extracted the stromal cell populations from a recently published study of fetal bone marrow. This provided the first comprehensive annotation of stromal cell subsets in human bone marrow (35), including endothelial, MSC, fibroblast, and osteochondral lineage subsets. Integration and unsupervised clustering showed a close approximation of organoid MSCs/fibroblasts ( $n = 687$ ) and endothelial cells ( $n = 766$ ) with the relevant cell clusters extracted from the human bone marrow dataset (endothelial,  $n = 766$  and MSCs/fibroblasts,  $n = 687$  cells; Supplementary Fig. S4A–S4C). As expected, osteolineage cells, chondrocytes, and smooth muscle and Schwann cells present in fetal bone marrow were absent from the organoids, and the distinct populations of sinusoidal and nonsinusoidal “tip” endothelial cells were also not detected. However, expression of adhesion proteins, cytokines, and hematopoietic support factors was very similar between organoid and bone marrow cells, including *CD34*, *PECAM*, *KITLG*, *FLT3LG*, and *ANGPT2* for endothelial cells (Fig. 4A) and *KITLG*, *PDGF*, and *VEGF* family members for MSCs/fibroblasts (Fig. 4B), confirming that the iPSC bone marrow organoid-derived stromal cells are highly homologous to their native bone marrow counterparts.

### Bone Marrow Organoids Recapitulate Cellular and Molecular Cross-talk between Hematopoietic, Endothelial, and Stromal Cells

To investigate the cellular and molecular interactions between hematopoietic, endothelial, and stromal cell subtypes within the organoids, we mapped the expression of interacting receptor and ligand pairs across clusters. Complex communication networks were detected, both within and between hematopoietic and stromal cell compartments (Fig. 4C). Strong autocrine and paracrine interactions were predicted between MSCs, fibroblasts, endothelial cells, and monocytes,

**Figure 2.** The addition of VEGFC induces specialization of organoid vasculature to a bone marrow sinusoid-like phenotype. **A**, In the sprouting phase of differentiation (D5) in hydrogels, organoids were supplemented with either VEGFA or VEGFC, or both VEGFA and VEGFC. **B**, mRNA expression of canonical cell-surface receptors, growth factors, and adhesion markers of bone marrow sinusoidal endothelium in VEGFA-, VEGFC-, and VEGFA + C-treated samples.  $\Delta\Delta C_t$  values relative to housekeeping (GAPDH) and undifferentiated iPSCs shown. Each datapoint represents 15 organoids; 3 independent differentiations shown. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$  for one-way ANOVA with multiple comparisons (Fisher least significant difference). **C**, *CD34*<sup>+</sup> sprouting vessels at day 12 in both VEGFA and VEGFA + C conditions. At day 18, vessels were *CD34* positive in VEGFA + C organoids but negative in VEGFA-only organoids. **D** and **E**, IHC staining for *CD34* (**D**) and hematoxylin and eosin (H&E) staining of formalin-fixed, paraffin-embedded VEGFA + C organoid sections (**E**), with inset showing lumen-forming vessels containing hematopoietic cells (blue arrows). **F**, Immunofluorescence staining of paraffin-embedded sections of VEGFA + C organoids showing *CD45*<sup>+</sup> hematopoietic (white arrow) and *CD71*<sup>+</sup> erythroid cells (yellow arrows) migrating into the *UAE1*<sup>+</sup> vessel lumen. **G**, Schematic demonstrating the process of proplatelet formation by megakaryocytes (MK; image created using Biorender.com). **H**, Whole organoid image showing *CD140b*<sup>+</sup> MSCs surrounding *CD144*<sup>+</sup> vessels with *CD41*<sup>+</sup> megakaryocytes. Insets show megakaryocytes extending proplatelet protrusions into vessel lumen (red arrows). Top inset shows *CD41*<sup>+</sup> platelet-like particles within vessel lumen. **I**, Confocal imaging and 3D render of whole-mount VEGFA + C organoids showing *CD41*<sup>+</sup> megakaryocytes (red arrow) closely associating with the *UAE1*<sup>+</sup> vessel network that is invested with *CD140b*<sup>+</sup> fibroblast/MSCs (blue arrow; left and center image). Inset (right) shows 3D rendered megakaryocytes displaying proplatelet formation (red arrow).






**Figure 4.** Endothelial cells (EC), fibroblasts, and MSCs from organoid stroma support hematopoiesis with increased hematopoietic support from VEGFA + C-stimulated vasculature. **A**, Comparison of expression of key receptors, adhesion proteins, and growth factors and chemokines in ECs from bone marrow organoids (Org.) and human fetal bone marrow (FBM). **B**, Comparison of expression of growth factors and chemokines in MSCs from organoids and FBM. Size of dots represents percentage of expressing cells, and color density indicates level of expression. **C**, Total predicted ligand-receptor interactions across clusters as predicted by CellPhoneDB (V2.0), showing extensive autocrine and paracrine interactions across BM organoid. MK, megakaryocyte; prog., progenitor. **D**, Volcano plot showing significantly differentially expressed (DE) genes in ECs from VEGFA + C versus VEGFA-only organoids (801 significantly upregulated and 700 significantly downregulated genes,  $P < 0.05$ ,  $\log_2$ FC  $> 0.5$  or  $-0.5$ ). **E**, Violin plots showing key hematopoietic support factors and markers of bone marrow sinusoidal endothelium in ECs of VEGFA + C and VEGFA-only organoids.  $P$  values are indicated below x-axis labels, and mean value is indicated on violin plots. \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.0001$  for pairwise comparison Wilcoxon test applied (FDR). UMI, unique molecular identifier. (continued on next page)

HSPCs, and megakaryocytes, whereas erythroid cells showed weak interactions (Fig. 4C; Supplementary Fig. S5A–S5C).

Numerous interacting receptor-ligand partners were detected between megakaryocytes and endothelial cells (Supplementary Figs. S5B and S6A), and megakaryocytes with MSCs (Supplementary Fig. S6B), indicating bidirectional regulatory interactions between these cell types. These included NOTCH1–JAG1/2, FLT4–PDGFC, ANGPT2–TEK, and FLT1–VEGFB for endothelium:megakaryocytes (Supplementary Figs. S5B and

S6A), and NOTCH1–DLL4, KIT–KITLG, FGF2–CD44, SELP–CD34, and VEGFRA–FLT1 for megakaryocytes:endothelial cells (Supplementary Fig. S6A). Interactions between megakaryocytes and MSCs were dominated by growth factors produced by megakaryocytes, including TGF $\beta$ , PDGF, FGF, and VEGF family members and their cognate receptors (Supplementary Fig. S6B).

Similarly, monocytes and endothelial cells demonstrated abundant interacting partners indicative of regulatory interactions, including TNF–NOTCH1, JAG1/2–NOTCH,



**Figure 4. (Continued) F-H.** Sankey plots comparing TGF $\beta$ 1-mediated (F), CXCL12-mediated (G), and CD44-mediated (H) interactions in VEGFA + C versus VEGFA-stimulated organoids. Endo, endothelial; Ery, erythroid; Fibro, fibroblast; Mono, monocyte; MSC, mesenchymal stem cell. **I.** Expression of interacting receptor-ligand pairs between organoid HSPCs and cognate partner in organoid or FBM ECs (endo) and MSCs/fibroblasts with percentage of expressing cells and level of expression shown. **J.** Hematopoietic cytokines/growth factors produced by bone marrow organoids, measured by Luminex assay. Each datapoint represents supernatant pooled from 16 separately generated organoids. See also Supplementary Figs. 4-7.

*SIRPA-CD47*, and *LGALS9*, *ICAM*, *VEGF* family members with cognate receptors (Supplementary Figs. S5C and S6C). Significantly interacting partners between monocytes and MSCs/fibroblasts included *CXCL12-CXCR4*, *ICAM1-αXb2*, *SPP1-CD44*, *IL1* and *IL16*, and hepatocyte and fibroblast growth factors with their respective binding partners (Supplementary Fig. S6D).

Although a high number of regulatory interactions between hematopoietic and stromal compartments were detected, interactions between the stromal cell subsets (endothelial cells:MSCs:fibroblasts) were particularly strong (Fig. 4C). Significantly interacting partners identified included key regulatory molecules such as *JAG-NOTCH*, *VEGF*, *DLL4-NOTCH3*, *PDGF-PDGFR*, *ANPT1/2-TEK*, *IL33-IL33R*, *FGF*, and *TGFB* (Supplementary Fig. S6E; refs. 36–38).

To explore the impact of the addition of VEGFC to the differentiation protocol on the phenotype of organoid vasculature, we compared the transcriptomes of endothelial cells captured from VEGFA- and VEGFA + C-derived bone marrow organoids by scRNA-seq. A total of 1,501 genes were significantly differentially expressed between endothelial cells generated with VEGFA only versus VEGFA + C, including 801 upregulated and 700 downregulated genes ( $P < 0.05$ ,  $\log_2\text{FC} > 0.5$  or  $-0.5$ ; Fig. 4D). Canonical markers of bone marrow sinusoidal endothelium were more highly expressed in endothelial cells from VEGFA + C organoids than VEGFA-only organoids, including *FLT4* (VEGFR4), *CD34*, *MCAM*, *ANGPT2*, *COL4A1*, *COL4A2*, *ITGA2*, *CDC42EP1*, and the notch ligand *DLL4* (25, 35), whereas *DLK1*—a negative regulator of hematopoiesis (39)—was significantly lower in VEGFA + C-stimulated organoids than in VEGFA-only (Fig. 4D and E).

In addition to improved hematopoietic support from endothelial cells, key regulatory axes were also upregulated across other cellular subsets in VEGFA + C organoids compared with VEGFA organoids (Fig. 4F–H). TGF $\beta$ 1 signaling primarily from MSCs, megakaryocytes, and fibroblasts was increased overall in VEGFA + C organoids across the different TGF $\beta$  receptors (Fig. 4F). Similarly, CXCL12 signaling via CXCR4 and ACKR3 receptors across both stromal and hematopoietic cell types was also elevated (Fig. 4G), whereas the impact of VEGFC on signaling between CD44 and its binding partners was more mixed (Fig. 4H).

The receptor-ligand communication networks predicted between hematopoietic cells and niche components in the organoid stroma mirrored many of the communication networks that have been reported in native bone marrow (35), including *CD44-SELE*, *CD74-APP*, *KIT-KITLG*, *ICAM3-ITGB2*, *CD46-JAG1*, and *NOTCH2-DLL4* (Fig. 4I).

Finally, we explored whether the expression of hematopoietic support factors detected in the bone marrow organoid niche cells by scRNA-seq (Supplementary Fig. S7A) could be confirmed at protein level. Organoids generated with VEGFA + C were harvested at day 18, washed, replated in media supplemented with L-Glutamine but no added cytokines or growth factors, and cultured for a further 12 days without any added supplements with 50:50 media changes every 72 hours. In the absence of exogenously supplied cytokines, the organoids secreted multiple hematopoietic factors including SCF/KITLG, CCL2–4, interleukins (IL2, 3, 4, 6, 7, 8, 11), PDGF, FLT3L, M-CSF, GM-CSF, and VEGF

(Fig. 4J; Supplementary Fig. S7B), confirming that the organoid stroma expresses key growth factors that might endogenously support hematopoiesis.


### Bone Marrow Organoids Model the TGF $\beta$ -Induced Bone Marrow Fibrosis That Occurs in Hematologic Cancers and Provide an Ex Vivo Platform for Inhibitor Screening

Pathologic hematopoietic niche remodeling occurs in the majority of hematologic malignancies. In certain cancers, particularly myeloproliferative neoplasms, myelodysplasia, acute leukemia, and mast cell neoplasms, bone marrow fibrosis is a major cause of bone marrow failure and morbidity and is associated with a poor prognosis (40). Fibrosis results from the excess production and release of profibrotic cytokines by hematopoietic cells—in particular TGF $\beta$ —leading to the deposition of reticulin and collagen fibers by marrow stroma (40–42). To investigate whether the organoids could model pathologic bone marrow fibrosis, we treated organoids with varying doses of TGF $\beta$  (10 ng/mL, 25 ng/mL, and 50 ng/mL), which resulted in a dose-dependent increase in the expression of hallmarks of fibrosis, including alpha smooth muscle actin ( $\alpha$ SMA [*ACTA2*]) and collagen 1 (*COL1A1*; Fig. 5A), both canonical markers of fibroblast activation (42). A significant increase in soluble IL11 was also observed (Fig. 5B; ref. 43). Collagen deposition within the organoids was markedly increased following TGF $\beta$  treatment (Fig. 5C), with pronounced reticulin fibrosis (Fig. 5D and E), recapitulating changes seen in the bone marrow of patients with myelofibrosis. The induction of organoid fibrosis was accompanied by reduced vascularization, suggesting multilineage remodeling as a consequence of TGF $\beta$  stimulation, as occurs in adult bone marrow (Fig. 5F and G).

We then explored the utility of this system to test potential inhibitors of fibrosis, selecting two compounds that inhibit pathways currently under investigation in clinical trials for myeloid malignancies—SB431542, an inhibitor of the TGF $\beta$  superfamily type I activin receptors, and the BET bromodomain inhibitor JQ1 (44). TGF $\beta$ -induced expression of soluble IL11 was completely inhibited by both treatments (Fig. 5H), whereas *ACTA2* and *COL1A1* overexpression was normalized by JQ1 and reduced by 1.5-fold and 2.5-fold, respectively, by SB431542 at the transcript level (Fig. 5I), and this reduction was also evident at the protein level by immunofluorescence imaging (Fig. 5J). Together, these data confirm that bone marrow organoids provide an efficient model of malignant bone marrow fibrosis and enable screening for the efficacy of potential pharmacologic modulators.

### Organoid “Niche Remodeling” and Fibrosis Occurs following Engraftment with Cells from Patients with Myelofibrosis but Not Healthy Donors

Having confirmed substantial homology to native bone marrow, we hypothesized that the organoids may support the engraftment of primary cells from patients with hematologic malignancies, enabling the modeling of cancer-stroma interactions and the possibility of patient-specific cytotoxic screens. Given the fibrosis observed following treatment with TGF $\beta$ , and the current lack of adequate



*in vitro* and *in vivo* systems for modeling cancer-induced bone marrow fibrosis, we first seeded the organoids with cells from healthy donors and patients with myelofibrosis, and tested the impact of engraftment on the remodeling of the bone marrow organoid “niche.”

Organoids were seeded with CD34<sup>+</sup> HSPCs from healthy donors ( $n = 7$ ) and patients with myelofibrosis ( $n = 10$ ; Supplementary Table S3). Donor cells were labeled with the plekstrin homology domain dye CellVue Claret, and 5,000 donor cells were seeded into each well of a 96-well ULA plate containing individual organoids (Fig. 6A). CellVue labeling enabled the identification and tracking of donor cells within the organoid milieu. Confocal Z-stack imaging confirmed that labeled cells from healthy donors and patients with myelofibrosis efficiently engrafted and were distributed throughout the organoid architecture (Fig. 6B; Supplementary Fig. S8A).

After 14 days, engrafted organoids were assessed for fibrosis. Soluble TGF $\beta$  levels were significantly elevated in the culture media of organoids engrafted with myelofibrosis cells when compared with healthy donor-engrafted samples (Fig. 6C). Immunofluorescence imaging showed a significant increase in collagen 1 and  $\alpha$ SMA in organoids engrafted with cells from patients with myelofibrosis at protein level (Fig. 6D and E; Supplementary Fig. S8B) as well as gene expression (Fig. 6F), with a concomitant decrease in expression of endothelial cell-associated genes *CDH5* and *TIE2* and vascularity (Fig. 6G–I).

Patient-derived CD34<sup>+</sup> HSPCs cultured within the organoids underwent lineage differentiation. After 14 days, a quarter (22%) of the total cells in the organoids were positive for the fluorescent label indicating adult donor origin, and these cells had undergone myeloid differentiation with erythroid (CD34<sup>−</sup> CD235<sup>+</sup> CD71<sup>+</sup>), myelomonocytic (CD34<sup>−</sup> CD45<sup>+</sup> CD11<sup>+</sup> CD14<sup>+</sup>), and megakaryocytic cell (CD34<sup>−</sup> CD41<sup>+</sup> CD42a<sup>+</sup>) immunophenotypes evident (Supplementary Fig. S9A). As expected, given the absence of lymphopoietic cytokines, no B or T cells were detected (Supplementary Fig. S9A and S9B). A small population of the label-positive cells retained CD34 expression even 14 days after seeding, and these cells showed lower rates of cell division, suggesting maintenance of a population of quiescent stem/progenitor cells in the organoids (Supplementary Fig. S9C) in addition to myeloid differentiation.

Crucially, the clonal architecture of the malignancies could be tracked following culture in the organoids. All mutations present in the HSPCs prior to seeding were detected in labeled cells sorted from the organoids 12 days after seeding, and at almost identical variant allele frequencies as the original sample (Fig. 6J).

## Patient Cell-Engrafted Organoids Allow for Testing of Potential Inhibitors of Fibrosis


We next assessed whether organoids engrafted with cells from patients with myelofibrosis enabled screening of potential inhibitors of fibrosis, to explore the utility of this platform for precision medicine approaches. Organoids seeded with cells from patients with myelofibrosis were cultured for 7 days and then treated with the TGF $\beta$  inhibitor SB431542, the BET inhibitor JQ1, or ruxolitinib (Fig. 6K). Only JQ1 treatment restored COL1A1 expression to the level seen in nonengrafted control organoids, and JQ1 also significantly reduced  $\alpha$ SMA (Fig. 6L and M). Expression of COL1A1 was lower following ruxolitinib treatment, with only a minimal reduction in  $\alpha$ SMA (Fig. 6L and M). Although SB431542 significantly inhibited the induction of COL1A1 and  $\alpha$ SMA in organoids in response to TGF $\beta$  treatment (Fig. 5I), no significant reversal was observed on hallmarks of fibrosis induced by engraftment of patient cells, suggesting that additional profibrotic signals derive from the myelofibrosis clone beyond TGF $\beta$  or an inability to reverse fibrosis once established.

## Bone Marrow Organoids Support the Engraftment, Survival, and Proliferation of Primary Cells from a Range of Hematologic Malignancies


Finally, we investigated whether primary human cells of other blood cancer types would also successfully engraft the bone marrow organoids. We focused on hematologic malignancies that are particularly challenging to maintain *ex vivo* and/or model *in vivo*—multiple myeloma, acute lymphoblastic leukemia (ALL), and myeloid leukemias—explored whether the organoids could improve the survival of cells *ex vivo*, thereby enabling mechanistic studies and target screening for these cancer types.

To test this, cryopreserved cells were thawed and fluorescently labeled prior to seeding into 96-well plates containing organoids. Cells from patients with multiple myeloma ( $n = 5$ ; Supplementary Table S4), ALL ( $n = 6$ , Supplementary Table S4), and chronic myeloid leukemia (CML;  $n = 2$ , Supplementary Table S3), a human AML cell line (THP-1), and leukemic cells from a human fetal liver-derived infant ALL xenograft model (Xeno iALL;  $n = 3$ , Supplementary Fig. S10) rapidly engrafted and were observed throughout the organoid volume (Fig. 7A and B). Distinct CellTrace-positive populations were detectable in the organoids for all 17 donor samples, confirming successful engraftment and survival of primary human and xenograft-derived cells over a 12-day time course (Supplementary Fig. S11A). Primary multiple myeloma cells were costained for CD38, confirming that cells derived from the malignant plasma cell clone had successfully engrafted (Fig. 7B).

**Figure 5.** Bone marrow organoids model TGF $\beta$ -induced bone marrow fibrosis and enable inhibitor screening. **A**, Organoids were treated with 10, 25, or 50 ng/mL recombinant TGF $\beta$  and evaluated by qRT-PCR for expression of *ACTA2* ( $\alpha$ SMA) and *COL1A1*, indicators of fibrosis. **B**, Soluble IL11 detected in organoid media following treatment of organoids with TGF $\beta$ . **C**, Confocal Z-stack images of whole, untreated, and TGF $\beta$  (50 ng/mL)-treated organoids stained for  $\alpha$ SMA and COL1A1. **D**, Reticulin staining of formalin-fixed, paraffin-embedded sections of TGF $\beta$ -treated organoids versus control. **E**, Measurement of total reticulin stained area in untreated and TGF $\beta$  (50 ng/mL)-treated organoids. **F** and **G**, CD34 immunostaining of organoid vessels (**F**) and quantification of total vascular area of organoids with/without TGF $\beta$  treatment (**G**). **H** and **I**, Effect of two potential inhibitors of TGF $\beta$ -induced fibrosis (SB431542 and JQ1) on IL11 secretion (**H**) and *ACTA2* and *COL1A1* expression (**I**). **J**,  $\alpha$ SMA and COL1A1 expression in TGF $\beta$ -treated organoids with/without indicated inhibitors. Representative images are shown. \*,  $P < 0.01$ ; \*\*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$  for one-way ANOVA with multiple comparisons (Fisher least significant difference). **T** tests performed for image analysis of paraffin-embedded sections (reticulin and CD34).  $n = 3$  with each repeat comprising 15 organoids pooled from 3 independent differentiations and treatments.



**Figure 6.** Engraftment of cells from patients with myelofibrosis, but not healthy donors, results in organoid "niche remodeling" and fibrosis. **A**, Cryopreserved peripheral blood or bone marrow cells from healthy donors and patients with blood cancers were fluorescently labeled, and 5,000 donor cells were seeded into each well of a 96-well plate containing individual organoids. Schematic created using BioRender.com. **B**, Maximum-intensity projection of confocal Z-stack of a whole engrafted organoid 72 hours after seeding of the wells with donor cells, indicating donor cells engrafted throughout the volume of the organoids. **C**, Soluble TGF $\beta$  in organoids engrafted by cells from patients with myelofibrosis and controls. **D–G**, Comparison of organoids engrafted with healthy donor and myelofibrosis cells for collagen 1 (COL1A1) and  $\alpha$ SMA immunofluorescence (**D**) and representative images (**E**), COL1A1 and ACTA2 gene expression (**F**), and CDH5 and TEK expression (**G**).  $n = 4$  healthy donors;  $n = 7$  myelofibrosis samples for qRT-PCR;  $n = 4$  healthy donors;  $n = 6$  myelofibrosis samples for imaging and quantification of cryosections. MFI, mean fluorescence intensity. **H** and **I**, Increased reticulin deposition with a concomitant reduction in vascular area in organoids engrafted with myelofibrosis (MF) cells versus nonengrafted control organoids with paired  $t$  tests; each datapoint corresponds to a single organoid engrafted with cells from 3 donors. **J**, Variant allele frequencies (VAF) of mutations detected by next-generation sequencing of cells from patients with myelofibrosis before seeding in organoids (day 0) compared with cells isolated by flow cytometry 12 days after culture in organoids, indicating maintenance of clonal architecture. (continued on following page)




**Figure 6. (Continued)** **K**, Workflow for organoid generation, engraftment with cells from patients with myelofibrosis, and treatment with inhibitors. **L**,  $\alpha$ SMA and collagen 1 expression in nonengrafted organoids, and organoids engrafted with myelofibrosis cells treated with DMSO (control), SB431542, JQ1, and ruxolitinib. Each data point corresponds to total measurements per organoid within a block ( $n = 3$  donors). One-way ANOVA with multiple comparisons (Fisher least significant difference). **M**, Representative images from **L**. Rux, ruxolitinib. \*,  $P < 0.01$ ; \*\*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$  for Mann-Whitney test. See also Supplementary Fig. S8.

Downloaded from <http://cancerdiscovery.aacrjournals.org/cancerdiscovery/article-pdf/1/3/329/3296889/32964.pdf> by guest on 30 October 2023

We compared the survival and proliferation of primary multiple myeloma, ALL, and Xeno iALL cells engrafted in the organoids with cells seeded in wells with media alone or into a single-lineage 3D coculture system containing primary human bone marrow MSCs in a Matrigel + collagen I hydrogel (3D BM-MSC). Whereas multiple myeloma cells were less than 20% viable only 48 hours after seeding in wells with media alone, in stark contrast, the myeloma cells expanded and remained >90% viable more than 12 days after

engraftment into organoids for all 5 donors tested (Fig. 7C and D). Similarly, the survival of primary ALL cells was significantly improved in the organoids compared with liquid culture (Fig. 7C). The cell viability for ALL and Xeno iALL was also higher in the organoids than in 3D BM-MSC cocultures (Fig. 7C), with higher proliferation rates (Fig. 7D and E). Plasma cells from patients with myeloma showed minimal cell division in either model (Fig. 7D), but the cells retained their original immunophenotype (CD38 $^+$ , CD319 $^+$ , and CD56 $^+$ )



more consistently in the organoids than in the 3D BM-MSC (Fig. 7F). Similarly, ALL and Xeno iALL cells showed improved maintenance of CD19 expression in the organoids as compared with 3D BM-MSC (Supplementary Fig. S12). Together, these data confirm that the organoids provide a supportive niche for the survival and growth of primary blood cancer cells from patients, including for cancer types that are otherwise poorly viable *ex vivo* and after cryopreservation.

## DISCUSSION

Here we describe the development of a protocol generating vascularized bone marrow organoids that faithfully model key cellular, molecular, and architectural features of myelopoietic bone marrow including stromal cells, lumen-forming vasculature, and myeloid cell types. We demonstrate the utility of these organoids for modeling cancer-induced perturbations to the bone marrow niche and myelofibrosis.

Treatment of organoids with TGF $\beta$ , the primary cytokine driving myelofibrosis, induced organoid fibrosis, enabling target prioritization and screening of potential inhibitors. Fibrosis also occurred following the engraftment of organoids with HSPCs from patients with myelofibrosis, but not healthy donors. The ability to reliably model bone marrow fibrosis is an important advance, as the lack of adequate *in vitro* and *in vivo* models currently hampers the efficient pre-clinical validation of strategies aiming to reduce or prevent fibrosis, which is a huge unmet need for patients with myeloproliferative neoplasms and other blood cancers (45). As the organoids are highly reproducible and feasible to generate at scale in 96- or 384-well plate formats, this system presents an ideal platform for high-throughput target screens using pharmacologic or genetic modulation.

We also show that cells from patients with both myeloid and lymphoid malignancies readily engraft and survive within the organoids, including cancer cell types that are notoriously difficult to maintain *ex vivo*. Remarkably, malignant cells from patients with multiple myeloma that had been cryopreserved and thawed prior to use were sustained by the organoids for 12 days, while rapidly losing viability when plated *in vitro* without stromal support. Maintenance of primary myeloma cells *ex vivo* and a method to study their interactions within a multicellular hematopoietic niche environment will enable preclinical pharmacogenomic screens and the study of disease mechanisms using primary cells from patients, which is currently a significant obstacle to translational research in this disease. Targeted genetic modification of organoids could be performed either by using lineage-specific promoters or by modulating the differentiation protocol to generate

certain cellular subsets (e.g., stroma) from wild-type iPSCs, and then assembling these with hematopoietic cells generated from a genetically modified parent iPSC line.

A key limitation of current human *ex vivo* bone marrow models has been a lack of sinusoidal-like endothelium, with many systems reliant on human umbilical vein endothelial cells (HUVEC; ref. 13). We show here that the addition of VEGFC, recently shown to support the bone marrow perivascular niche (28), drives the generation of vasculature and supporting stroma that are specialized for hematopoietic support and phenocopy bone marrow sinusoidal endothelium. The resulting bone marrow organoids thereby present a unique opportunity to study the hematopoietic-niche cross-talk that underpins healthy hematopoiesis, and how perturbations to these regulatory interactions are permissive for the emergence and progression of cancers.

Although this system offers a substantial advance in the field, in its current iteration, no osteoid lineage, lymphoid cells, smooth muscle cells, or adipocytes are generated. Similarly, although we show a high degree of homology of the organoid vasculature to sinusoidal endothelium from human bone marrow, distinct arteriolar, and sinusoidal endothelial subtypes are not present in the organoids. The current differentiation protocol was optimized primarily to study myeloid malignancies and cancer-associated bone marrow fibrosis, and refinement of the growth factor supplements may improve the maintenance of lymphoid malignancies. In addition, the introduction of recirculating flow (46) may allow for the generation of organoids that mimic native bone marrow physiology more comprehensively. Despite these limitations, maintenance of cells from B-cell leukemias and plasma cell malignancies as well as myeloid cancers provides proof of principle that bone marrow organoids can be used to support a range of bone marrow cancers and cell types, paving the way for customization to support other relevant studies.

A protocol for the ectopic implantation of human bone marrow MSC-derived ossicles has previously been shown to support the engraftment of adult HSCs *in vivo* (47). Although the iPSC-derived organoids are not an *in vivo* system, they are substantially more efficient to generate than *in vivo* ossicles (weeks vs. months) and do not require human bone marrow or platelet lysates, which are hard to source and may induce experimental variability. The survival and continuous production of hematopoietic support factors in the absence of exogenous cytokine supplementation suggest that longer-term cultures may be possible. The implantation of organoids into mice has not yet been tested but may allow for longer-term studies in an *in vivo* setting.

**Figure 7.** Bone marrow organoids support the engraftment, survival, and proliferation of cells from patients with myeloid and lymphoid hematologic malignancies. **A**, Organoids engrafted with CellVue-labeled model infant ALL cells from xenografts (Xeno iALL), primary cells from a patient with untreated CML, and THP-1 cells, an acute myeloid leukemia cell line. CellVue<sup>+</sup> cells are visible throughout the volume of organoids. **B**, Organoids seeded with CD138<sup>+</sup> cells isolated from bone marrow aspirates of patients with multiple myeloma show CellVue<sup>+</sup> CD38<sup>+</sup> plasma cell engraftment. **C–E**, Viability and proliferation of cells from 4 donors with multiple myeloma, 6 donors with ALL, and 3 Xeno iALL samples seeded simultaneously in the organoids, a 3D coculture with primary human BM-MSC (3D BM-MSC), and where possible, liquid culture. **E**, Serial dilution of CellTrace label, indicating cell proliferation, for multiple myeloma, Xeno iALL, and ALL cells in 3D BM-MSC and organoids on days 2, 5, 7, and 12 following thawing and plating. **F**, Engrafted multiple myeloma cells retained their immunophenotype at day 12 with more consistent maintenance of CD319 and CD38 in organoids than 3D BM-MSC. Representative images are shown. \*, P < 0.01; \*\*, P < 0.001; ns, not significant. n = 4 for multiple myeloma, n = 3 for Xeno iALL, and n = 3 for ALL, with each repeat comprised of a separate donor two-way ANOVA with repeated measures and multiple comparisons (organoid cultures vs. 3D BM-MSC; Fisher least significant difference) for ALL and multiple myeloma and multiple unpaired t test for Xeno iALL data. BM, bone marrow; FSC, forward scatter.

The development of organoids has been transformative in other disease settings—for example, cerebral, lung, and kidney disease modeling (48). This platform may similarly be an enabling technology for the interrogation of disease mechanisms in hematologic cancers as well as the development and testing of novel therapies using human cells in a tissue-relevant system. Importantly, this platform is likely to reduce reliance on animal models. Target identification and screening using a species-specific, clinically relevant *ex vivo* model that can incorporate primary cells from patients may accelerate and increase the success rate of clinical translation.

## METHODS

### iPSC Culture and Differentiation

A Gibco Human Episomal iPSC (Thermo Fisher Scientific, cat. #A18945) line was maintained in StemFlex medium (Thermo Fisher Scientific, cat. #A3349401) and on Geltrex (Thermo Fisher Scientific, cat. #A1569601)-coated 6-well plates. The iPSC line was karyotyped prior to use (23), and potency markers were assessed upon expansion and freezing. A full, detailed description of passaging and differentiation protocols is included in Supplementary Materials and Methods. In brief, for differentiations, iPSCs were dissociated using EDTA when colonies were approximately 100  $\mu$ m in diameter. The resulting iPSC aggregates were incubated overnight in StemFlex supplemented with RevitaCell in 6-well Co-star ULA plates (Corning, cat. #3471; day -1). After overnight incubation, cells were collected and resuspended in phase I medium (Supplementary Methods) and cultured at 5% O<sub>2</sub> for 3 days (days 0–3). Aggregated cells were then collected again in phase II medium (Supplementary Methods). On day 5, cells were collected by gravitation for hydrogel embedding. Hydrogels were composed of 60% collagen (either type I, type IV, or an equal parts type I + IV mix) and 40% Matrigel as detailed in Supplementary Methods. Fully polymerized gels with cell aggregates were then supplemented with phase III media (Supplementary Methods). Media were replenished every 72 hours.

### Immunofluorescence Staining

Sections were blocked using 2% goat serum (Thermo Fisher Scientific, cat. #31872) and 1% bovine serum albumin (BSA; Sigma, cat. #A9418) prior to primary antibody labeling with antibody diluted in 1% BSA, sequential PBS washes, and secondary labeling with AlexaFluor conjugates. The whole organoid blocking solution was supplemented with Triton X100, Tween, and sodium deoxycholate as described by Wimmer and colleagues (21). Antibodies are listed in Supplementary Table S5, and additional details are given in Supplementary Methods.

### scRNA-seq, Data Processing, and Analysis

Cryopreserved cells pooled from 15 organoids from 3 differentiations from both VEGFA and VEGFA + C protocols were processed for single-cell sequencing as described in Supplementary Methods, and processed using the Chromium Single-Cell 3' library and Gel Bead Kits v3.1 (10X Genomics) as per kit instructions. Demultiplexed FASTQ files were aligned to the human reference genome (GRCh38/hg38) using standard CellRanger (version 6.0.1) “cellranger count” pipeline (10X Genomics). SingCellaR (ref. 31; <https://supatt-lab.github.io/SingCellaR.Doc/>) was used for the downstream analysis.

### Flow Cytometry

Organoids were dissociated for flow cytometry analysis using collagenase type II (Sigma-Aldrich, cat. #C6885) resuspended in HEPES buffer (Sigma-Aldrich, cat. #H0887) at a concentration of 20 mg/mL.

Samples were collected by gravitation in a 15-mL Falcon tube and washed 2x in PBS and then resuspended in collagenase type II. For dissociation, samples were incubated at 37°C for 5 minutes before trituration and a further 5-minute incubation. The dissociation reaction was stopped through the addition of PBS supplemented with FBS. Ten organoids were dissociated per flow cytometry experiment. Analysis was performed using either a cyan flow cytometer (Beckman Coulter) or an Attune NxT. Single color stained controls and fluorescence-minus-one controls were used for all experiments using antibodies as listed in Supplementary Table S5.

### TGF $\beta$ Treatment to Induce Organoid Fibrosis

Organoids were treated with TGF $\beta$  (PeproTech, cat. #100-21) at 10, 25, or 50 ng/mL for 72 hours. At 72 hours, all samples were approximately 90% viable after collagenase digestion. Samples were then collected for either whole-mount microscopy, paraffin/OCT embedding and sectioning, or qRT-PCR. Thirty-two organoids were treated per replicate; of these, 16 were spun down for RNA extraction for subsequent qRT-PCR. The remaining 16 organoids were fixed, with 8 taken for whole volume imaging and 8 per repeat taken for embedding and sectioning. For drug treatment, samples were treated with DMSO or TGF $\beta$  at a concentration of 25 ng/mL, and supplemented with an inhibitor as described (either JQ1 at 0.5  $\mu$ mol/L or SB431542 at 20  $\mu$ mol/L).

### qRT-PCR

Whole organoids were processed using either the Micro RNeasy Kit (Qiagen, cat. #74004) or Qiagen Mini RNA isolation kit (Qiagen, cat. #74104) as per kit instructions. cDNA was prepared using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, cat. #4368814) or EvoScript Universal cDNA Master (Roche, cat. #07912374001), and RT-PCR was performed using PowerUp SYBR Green Master Mix reagent (Applied Biosystems, cat. #A25742) or TaqMan Universal PCR Master Mix (Applied Biosystems; see Supplementary Table S6 for a list of primers).

### Seeding of Organoids and 3D BM-MSC Cultures with Hematopoietic Cells

Peripheral blood and bone marrow samples were collected from healthy donors and patients with hematologic malignancies following the provision of written informed consent in accordance with the Declaration of Helsinki. All participants donated human tissue for research without receiving monetary compensation, and the studies were approved by an institutional review board [myelofibrosis, CML, and G-CSF mobilized healthy apheresis donors—INForMed Study, University of Oxford (IRAS: 199833; REC 16/LO/1376); multiple myeloma—Oxford Radcliffe Biobank (Oxford Clinical Research Ethics Committee 09/H0606/5/5, project 16/A185); ALL samples: REC 16/LO/2055' (IRAS 179685)]. Written informed consent was received from all the participants for the donation of human tissue.

For engraftments with CD34 $^+$  HSPCs, cryopreserved mononuclear cells were thawed and CD34 $^+$  viable cells were FACS isolated using a Becton Dickinson FACSaria Fusion Cell Sorter with 100-nm nozzles into 1.5 mL Eppendorf tubes prior to seeding in organoids. For inhibitor experiments, organoids were engrafted with CD34 $^+$  myelofibrosis cells and cultured for 7 days prior to the addition of inhibitors. Myeloma cells were selected from total bone marrow mononuclear cells using anti-CD138 magnetic bead enrichment (STEMCELL Technologies, cat. #17887) prior to cryopreservation. Xeno iALL cells were derived from a recently published xenograft model of infant ALL in which the t(4;11)/MLL-AF4 translocation was introduced into primary human fetal liver hematopoietic cells by CRISPR-Cas9 gene editing prior to transplantation into immuno-deficient mice (49). All experiments were performed under a project

license approved by the UK Home Office under the Animal (Scientific Procedures) Act 1986 after approval by the Oxford Clinical Medicine Animal Welfare and Ethical Review Body and in accordance with the principles of 3Rs (replacement, reduction, and refinement) in animal research. Cells were harvested from the bone marrow of leukemic mice at 17 to 18 weeks, and total bone marrow cells were cryopreserved. Following thawing and prior to seeding in the organoids, human CD45<sup>+</sup> were selected using magnetic microbeads (Miltenyi Biotec, cat. #130-045-801). Over 90% of human CD45<sup>+</sup> cells were CD19<sup>+</sup> CD34<sup>+</sup> lymphoblasts with a predominantly CD34<sup>+</sup> pro-B phenotype (CD10<sup>+</sup>CD20<sup>+</sup>IgM/IgD<sup>-</sup>; Supplementary Fig. S10). Informed consent was provided by all participants for the donation of human tissue, and this study was approved by an institutional review board (REC: 18/NE/0290 and 18/LO/0822). The replicates included in this study were from 4 mice transplanted with MLL-AF4-edited cells from one human fetal liver sample. Details of donor cell labeling are included in Supplementary Materials and Methods. The composition of the engrafted organoids was analyzed by flow cytometry using either an LSRII Fortessa X50 (BD Biosciences) or an Attune NxT or a next-generation sequencing panel (see Supplementary Methods and Supplementary Table S7).

For the 3D BM-MSC cocultures, 24-well plates were prepared containing 300  $\mu$ L of a 70:30 mix of collagen I:Matrigel per well and incubated at 37°C for 90 minutes. Primary bone marrow MSCs resuspended at 10,000 cells/mL in StemPro-34 supplemented medium were added to the wells (500  $\mu$ L/well) and incubated overnight prior to seeding with primary hematopoietic cells.

### Data Analysis Software

scRNA-seq analyses were performed in R Studio (version 1.4.1106). Other statistical analyses were performed using GraphPad PRISM 7 with statistical tests as described in relevant figure legends. *P* values are defined as \*, *P* < 0.01; \*\*, *P* < 0.05; \*\*\*, *P* < 0.001; \*\*\*\*, *P* < 0.0001.

### Data Availability

scRNA-seq data are available at the Gene Expression Omnibus (accession GSE196684). Scripts used for analysis are available at <https://github.com/aokhan/BMorganoidV1/> and <https://github.com/supatt-lab/SingCellaR>. Further data are available on request.

### Authors' Disclosures

A.O. Khan and B. Psaila are coinventors on a pending patent (GB2202025.9 and GB2216647.4) relating to data in this article. A.-A. Olijnik reports grants from Cancer Research UK during the conduct of the study. N. Sousos reports personal fees from Bristol Myers Squibb, and grants from Bristol Myers Squibb and AOP Orphan outside the submitted work. C. Simoglu Karali reports grants and personal fees from Bristol Myers Squibb outside the submitted work. D. Bassett reports other support from CLEXBio outside the submitted work. S. Gooding reports grants from Bristol Myers Squibb, Innovate UK (UKRI), and Cancer Research UK outside the submitted work. B. Psaila reports grants from Cancer Research UK Advanced Clinician Scientist Fellowship and British Research Council Senior Research Fellowship during the conduct of the study, as well as grants, personal fees, and other support from Alethiomics, personal fees from Novartis and Blueprint Medicines, and grants from Galeto and Constellation Therapeutics outside the submitted work. No disclosures were reported by the other authors.

### Authors' Contributions

**A.O. Khan:** Conceptualization, resources, data curation, formal analysis, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, project administration, writing—review and editing. **A. Rodriguez-Romera:** Formal analysis,

investigation. **J.S. Reyat:** Investigation, methodology, writing—review and editing. **A.-A. Olijnik:** Investigation, writing—review and editing. **M. Colombo:** Formal analysis, investigation, writing—review and editing. **G. Wang:** Data curation, software, formal analysis, investigation, visualization, writing—review and editing. **W.X. Wen:** Software, investigation, methodology, writing—review and editing. **N. Sousos:** Formal analysis, investigation, writing—review and editing. **L.C. Murphy:** Investigation. **B. Grygielska:** Investigation. **G. Perrella:** Formal analysis, investigation. **C.B. Mahony:** Software, investigation, writing—review and editing. **R.E. Ling:** Formal analysis, investigation, writing—review and editing. **N.E. Elliott:** Formal analysis, investigation. **C. Simoglu Karali:** Investigation. **A.P. Stone:** Investigation. **S. Kemble:** Software, investigation. **E.A. Cutler:** Resources, validation, writing—original draft. **A.K. Fielding:** Conceptualization, resources, writing—review and editing. **A.P. Croft:** Supervision. **D. Bassett:** Supervision, funding acquisition. **G. Poologasundarampillai:** Funding acquisition, methodology. **A. Roy:** Resources, investigation, writing—review and editing. **S. Gooding:** Resources, investigation, writing—review and editing. **J. Rayes:** Formal analysis, investigation, writing—review and editing. **K.R. Machlus:** Resources, supervision, funding acquisition, writing—review and editing. **B. Psaila:** Conceptualization, resources, formal analysis, supervision, funding acquisition, methodology, writing—original draft, project administration, writing—review and editing.

### Acknowledgments

A.O. Khan is funded by a Sir Henry Wellcome fellowship (218649/Z/19/Z). K.R. Machlus is supported by grants from the NIH, the National Institute of Diabetes and Digestive and Kidney Diseases (R03DK124746), and the National Heart, Lung, and Blood Institute (R01HL151494) and is an American Society of Hematology Scholar. G. Wang was supported by an Oxford Centre for Haematology Pump Priming Award and a Medical Science Division Pump Priming Award (009800) from the Nuffield Benefaction for Medicine and the Wellcome Institutional Strategic Support Fund (ISSF). A.K. Fielding is supported by the Cancer Research UK award C27995/A21019 (also awarded to Anthony V. Moorman), which allowed for biobanking and specimen collection from UKALL14. G. Perrella is supported by funding from the Engineering and Physical Sciences Research Council (EP/V051342/1). S. Gooding receives funding from a Cancer Research UK Clinician Scientist Fellowship (RCCCSF-Nov21\100004) and unit funding from the Medical Research Council (awarded to the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine). B. Psaila receives funding from a Cancer Research UK Advanced Clinician Scientist Fellowship (C67633/A29034), a British Research Council (BRC) Senior Research Fellowship, the Haematology and Stem Cells Theme of the Oxford BRC, a Kay Kendall Leukemia Fund Project Grant, and unit funding from the Medical Research Council (awarded to the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine). A CC BY or equivalent license is applied to the author accepted manuscript arising from this submission in accordance with the funders' open access conditions. We thank all the patients who kindly donated samples and Nawshad Hayder and Sophie Reed who helped with sample banking; the University of Birmingham TechHub Imaging Core Facilities and staff; the MRC WIMM Flow Cytometry Facility; the MRC WIMM Single Cell Facility; Daniel Royston for input and advice on bone marrow architecture and histology; Zewen Kelvin Tuong for assistance with KT Plots Scripting; and Arturs Habirovs and Ashleigh Danks for computational advice.

The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

## Note

Supplementary data for this article are available at *Cancer Discovery* Online (<http://cancerdiscovery.aacrjournals.org/>).

Received February 21, 2022; revised October 4, 2022; accepted November 7, 2022; published first November 9, 2022.

## REFERENCES

1. Baryawno N, Przybylski D, Kowalczyk MS, Kfoury Y, Severe N, Gustafsson K, et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. *Cell* 2019;177:1915–32.
2. Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, et al. Bone marrow niches in hematological malignancies. *Nat Rev Cancer* 2020;20:285–98.
3. Tikhonova AN, Dolgalev I, Hu H, Sivaraj KK, Hoxha E, Cuesta-Domínguez Á, et al. The bone marrow microenvironment at single-cell resolution. *Nature* 2019;569:222–8.
4. Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. *Cell Stem Cell* 2021;28:637–52.
5. Celik H, Krug E, Zhang CR, Han W, Issa N, Koh WK, et al. A humanized animal model predicts clonal evolution and therapeutic vulnerabilities in myeloproliferative neoplasms. *Cancer Discov* 2021;11:3126–41.
6. Lysenko V, Wildner-Verhey van Wijk N, Zimmermann K, Weller MC, Bühler M, Wildschut MHE, et al. Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. *Blood Adv* 2020;4:2477–88.
7. Nicolini FE, Cashman JD, Hogge DE, Humphries RK, Eaves CJ. NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. *Leukemia* 2004;18:341–7.
8. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, et al. Development and function of human innate immune cells in a humanized mouse model. *Nat Biotechnol* 2014;32:364–72.
9. Willinger T, Rongvaux A, Takizawa H, Yancopoulos GD, Valenzuela DM, Murphy AJ, et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. *Proc National Acad Sci* 2011;108:2390–5.
10. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. *Leukemia* 2010;24:1785–8.
11. Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. *Nat Med* 2016;22:1351–7.
12. Chou DB, Frismantas V, Milton Y, David R, Pop-Damkov P, Ferguson D, et al. On-chip recapitulation of clinical bone-marrow toxicities and patient-specific pathophysiology. *Nat Biomed Eng* 2020;4:394–406.
13. Janagama D, Hui SK. 3-D cell culture systems in bone marrow tissue and organoid engineering, and BM phantoms as in vitro models of hematological cancer therapeutics—a review. *Materials* 2020;13:5609.
14. Raic A, Naolou T, Mohra A, Chatterjee C, Lee-Thedieck C. 3D models of the bone marrow in health and disease: yesterday, today, and tomorrow. *Mrs Commun* 2019;9:37–52.
15. Buduo CAD, Wray LS, Tozzi L, Malara A, Chen Y, Ghezzi CE, et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. *Blood* 2015;125:2254–64.
16. Tozzi L, Laurent P-A, Buduo CAD, Mu X, Massaro A, Bretherton R, et al. Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production. *Biomaterials* 2018;178:122–33.
17. Bessy T, Itkin T, Passaro D. Bioengineering the bone marrow vascular niche. *Frontiers Cell Dev Biology* 2021;9:645496.
18. Bourgine PE, Klein T, Paczulla AM, Shimizu T, Kunz L, Kokkaliaris KD, et al. In vitro biomimetic engineering of a human hematopoietic niche with functional properties. *Proc National Acad Sci* 2018;115:E5688–95.
19. Adamo A, Delfino P, Gatti A, Bonato A, Kamga PT, Bazzoni R, et al. HS-5 and HS-27A stromal cell lines to study bone marrow mesenchymal stromal cell-mediated support to cancer development. *Frontiers Cell Dev Biology* 2020;8:584232.
20. Veninga V, Voest EE. Tumor organoids: Opportunities and challenges to guide precision medicine. *Cancer Cell* 2021;39:1190–201.
21. Wimmer RA, Leopoldi A, Aichinger M, Wick N, Hantsch B, Novatchkova M, et al. Human blood vessel organoids as a model of diabetic vasculopathy. *Nature* 2019;565:505–10.
22. Feng Q, Shabraní N, Thon JN, Huo H, Thiel A, Machlus KR, et al. Scalable generation of universal platelets from human induced pluripotent stem cells. *Stem Cell Rep* 2014;3:817–31.
23. Khan AO, Slater A, Maclachlan A, Nicolson PLR, Pike JA, Reyat JS, et al. Post-translational polymodification of  $\beta$ 1-tubulin regulates motor protein localisation in platelet production and function. *Haematologica* 2020;107:243–60.
24. Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, et al. Distinct bone marrow blood vessels differentially regulate hematopoiesis. *Nature* 2016;532:323–8.
25. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. *Physiology* 2005;20:349–56.
26. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. *Cell* 2019;176:1248–64.
27. Durán JGB, Lu T, Houghton S, Geng F, Schreiner R, Xiang J, et al. Endothelial Jak3 expression enhances pro-hematopoietic angiocrine function in mice. *Commun Biology* 2021;4:406.
28. Fang S, Chen S, Nurmi H, Leppänen VM, Jeltsch M, Scadden D, et al. VEGF-C protects the integrity of the bone marrow perivascular niche in mice. *Blood* 2020;136:1871–83.
29. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, et al. Dynamic visualization of thrombopoiesis within bone marrow. *Science* 2007;317:1767–70.
30. Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. *Mol Cell* 2020;78:477–92.
31. Roy A, Wang G, Iskander D, O'Byrne S, Elliott N, O'Sullivan J, et al. Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development. *Cell Rep* 2021;36:109698.
32. JMME de K Z, Papazian N, Tahri S, BDH op, Hoogenboezem R, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. *Nat Immunol* 2021;22:769–80.
33. Popescu DM, Botting RA, Stephenson E, Green K, Webb S, Jardine L, et al. Decoding human fetal liver haematopoiesis. *Nature* 2019;574:365–71.
34. Kang JB, Nathan A, Weinand K, Zhang F, Millard N, Rumker L, et al. Efficient and precise single-cell reference atlas mapping with Symphony. *Nat Commun* 2021;12:5890.
35. Jardine L, Webb S, Goh I, Londoño MQ, Reynolds G, Mather M, et al. Blood and immune development in human fetal bone marrow and Down syndrome. *Nature* 2021;598:327–31.
36. Sweeney M, Foldes G. It takes two: endothelial-perivascular cell cross-talk in vascular development and disease. *Frontiers Cardiovasc Medicine* 2018;5:154.
37. Hirano K, Suganami A, Tamura Y, Yagita H, Habu S, Kitagawa M, et al. Delta-like 1 and Delta-like 4 differently require their extracellular domains for triggering Notch signaling in mice. *Elife* 2020;9:e50979.
38. Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells

derived from chronic lymphocytic leukemia: implications for an angiogenic switch. *Blood* 2010;116:2984–93.

39. Mirshekar-Syahkal B, Haak E, Kimber GM, LK van, Harvey K, O'Rourke J, et al. Dlk1 is a negative regulator of emerging hematopoietic stem and progenitor cells. *Haematologica* 2013;98:163–71.
40. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. *Brit J Haematol* 2007;139:351–62.
41. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF- $\beta$  signaling in fibrosis. *Growth Factors* 2011;29:196–202.
42. Kramann R, Schneider RK. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. *Blood* 2018;131:2111–9.
43. Cominal JG, Cacemiro M da C, Berzoti-Coelho MG, Pereira IEG, Frantz FG, Souto EX, et al. Bone marrow soluble mediator signatures of patients with philadelphia chromosome-negative myeloproliferative neoplasms. *Frontiers Oncol* 2021;11:665037.
44. Morsia E, Gangat N. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets. *Expert Opin Ther Tar* 2021;25:1–12.
45. Waksal JA, Harrison CN, Mascarenhas JO. Novel therapeutics and targets in myelofibrosis. *Leuk Lymphoma* 2022;63:1020–33.
46. Homan KA, Gupta N, Kroll KT, Kolesky DB, Skylar-Scott M, Miyoshi T, et al. Flow-enhanced vascularization and maturation of kidney organoids in vitro. *Nat Methods* 2019;16:255–62.
47. Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. *Nat Med* 2016;22:812–21.
48. Bock C, Boutros M, Camp JG, Clarke L, Clevers H, Knoblich JA, et al. The organoid cell atlas. *Nat Biotechnol* 2021;39:13–7.
49. Rice S, Jackson T, Crump NT, Fordham N, Elliott N, O'Byrne S, et al. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program. *Nat Commun* 2021;12:6905.